Evolent Health Q2 revenue beats expectations

Evolent Health

06/08/2026 12:32

Overview
US healthcare solutions firm's Q2 revenue rose and beat analyst expectations
Company posted a net loss for Q2, but loss narrowed from prior year
Full-year 2026 revenue guidance raised, adjusted EBITDA outlook tightened

Outlook
Evolent raises 2026 revenue guidance to $2.6-$2.7 bln
Company tightens 2026 Adjusted EBITDA guidance to $120-$135 mln
Evolent expects 2027 revenue growth of over 25% versus 2026

Result Drivers
SPECIALTY CARE DEMAND - Co said rising medical costs for health plans drove robust demand for its complex specialty care solutions, especially oncology
NEW AND EXPANDED PARTNERSHIPS - Co highlighted new Oncology Performance Suite partnership and expanded Specialty Technology & Services Suite contract as contributors to growth
HIGHER MEDICAL COSTS - Co reported a higher medical expense ratio, reflecting increased medical costs relative to revenue

Company press release: ID:nPn3y0C76a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$652.52 mln
$598 mln (15 Analysts)
Q2 Net Loss
 
$28.36 mln
 
Q2 Adjusted EBITDA
 
$28.05 mln
 
Q2 Adjusted EBITDA Margin
 
4.30%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Evolent Health, Inc. is $6.00, about 94.8% above its August 5 closing price of $3.08
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 17 three months ago

Reuters Recommended Reads
Aug 5 - Agilon Health Q2 revenue beats estimates, raises outlook
Aug 6 - Oscar Health beats Q2 revenue estimates, raises 2026 outlook
Aug 5 - McKesson raises annual profit forecast on strong growth in specialty drug business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)